Avid Bioservices, Inc.

CDMO

US05368M1062

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 08:21:17 04/06/2024 pm IST			5-day change	1st Jan Change
7.895 ^USD	-0.94%		-8.33%	+21.57%

30/04	RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	MT
29/04	Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024

Avid Bioservices, Inc. Reaffirms Revenue Guidance for the Full Year of 2022

September 09, 2021 at 01:55 am IST

Avid Bioservices, Inc. reaffirmed revenue guidance for the full year of 2022. The company is confirming revenue guidance for the full fiscal year 2022 of $115 million to $117 million.

Latest news about Avid Bioservices, Inc.

RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	30/04	MT
Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024	30/04
Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	25/04	CI
North American Morning Briefing : Stock Futures -2-	19/04	DJ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	05/04	DJ
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
Avid Bioservices Receives Nasdaq Noncompliance Notice	20/03	MT
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	15/03	DJ
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating	11/03	MT
Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump	08/03	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Buoyed by Powell's Comments	07/03	MT
Top Premarket Decliners	07/03	MT
Avid Bioservices Shares Slide After Pricing Private Placement of Convertible Notes	07/03	DJ
Avid Bioservices Prices $160 Million Convertible Notes Offering	07/03	MT
Avid Bioservices Preliminary Fiscal Q3 Revenue Falls 11%; $160 Million Private Placement of Notes Set; Shares Slump	07/03	MT
Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024	07/03	CI
Avid Bioservices, Inc. announced that it expects to receive $160 million in funding	06/03	CI
In moon race with China, U.S. setbacks test role of private firms	12/01	RE
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 1000	18/12	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 600 Health Care	18/12	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Composite 1500	18/12	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 600	18/12	CI
Craig-Hallum Adjusts Avid Bioservices' Price Target to $16 From $22, Maintains Buy Rating	08/12	MT
Avid Bioservices Faces Uphill Battle as Overall Demand Environment Poses Challenges, RBC Says	08/12	MT
KeyBanc Cuts Price Target on Avid Bioservices to $14 From $20, Maintains Overweight Rating	08/12	MT

Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Companyâs services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.

Sector

Pharmaceuticals

Calendar

26/06/2024 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Avid Bioservices, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.97 USD

Average target price

12.5 USD

Spread / Average Target

+56.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AVID BIOSERVICES, INC.	+21.57%	506M
CSL LIMITED	-1.62%	90.85B
SAMSUNG BIOLOGICS CO.,LTD.	-1.05%	39.02B
BIOGEN INC.	-9.98%	33.46B
BIOMARIN PHARMACEUTICAL INC.	-18.69%	14.51B
INCYTE CORPORATION	-6.10%	13.22B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.42%	11.65B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-47.67%	10.57B
SWEDISH ORPHAN BIOVITRUM AB	+6.29%	9.23B
ALTEOGEN INC.	+102.03%	7.71B

Biopharmaceuticals